Video

Q&A With Hayes Dansky From Janssen: New Research Opens the Door for Xarelto for Atrial Fibrillation Patients

Author(s):

As one of the newest anticoagulants on the market new research has opened the door for more patients to use Xarelto as part of their treatment regimen over the years.

As one of the newest anticoagulants on the market new research has opened the door for more patients to use Xarelto as part of their treatment regimen over the years.

Hayes Dansky, MD, from Janssen Pharmaceuticals discussed how a recent study showed the benefits of taking the medication for patients with nonvalvular atrial fibrillation during the American Heart Association's annual scientfic sessions in Orlando. The medication has been shown to help prevent strokes in these patients and also showed positive results for major bleeding.

Related Videos
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
Orly Vardeny, PharmD | Credit: JACC Journals
Christian T. Ruff, MD, MPH: Abelacimab Cuts Bleeding Risk Versus Rivaroxaban| Image Credit: Brigham & Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.